Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?
Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?
复制标题
DOI：
10.1089/hum.2015.29014.kib
复制
发表时间：
2015-12-01
影响因子：
4.2
通讯作者：
Srivastava, Arun
中科院分区：
文献类型：
--
作者：
Berns, Kenneth I.;Byrne, Barry J.;Srivastava, Arun
在最近一篇题为“人类肝细胞癌中与 AAV2 相关的反复插入突变”的 Nature Genetics 信件中，Nault 及其同事记录了 193 名肝细胞癌 (HCC) 患者中，11 名患者含有野生型腺相关病毒 2 (AAV2) 的整合基因组序列，并表明 AAV2 与 人类 HCC 中的致癌插入突变。由于 AAV2 长期以来一直被认为是一种非致病性人类细小病毒2，并且事实上已被证明具有抗肿瘤活性，3-6 因此，严格评估这些研究的科学和临床意义以证明其结论是至关重要的。我们仔细分析了诺特及其同事提供的数据，并得出了与作者的结论不一致的结论。
IN A RECENT Nature Genetics letter, entitled ‘‘Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas,’’Nault and colleagues1 document that of 193 patients with hepatocellular carcinoma (HCC), 11 contained an integrated genome sequence of the wild-type adenoassociated virus 2 (AAV2), and suggest that AAV2 is associated with oncogenic insertional mutagenesis in human HCC.Because AAV2 has long been known to be a nonpathogenic human parvovirus2 and, in fact, has been shown to possess antitumor activity, 3–6 it is critical that the scientific and clinical implications of these studies be rigorously assessed to justify their conclusions. We have carefully analyzed the data presented by Nault and colleagues1 and reached a conclusion that is at variance with that of the authors.